Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Colson, P. Articles by Tamalet, C. Search for Related Content PubMed PubMed Citation Articles by Colson, P. Articles by Tamalet, C.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, April 2006, p. 1602-1603, Vol. 44, No. 4
0095-1137/06/$08.00+0     doi:10.1128/JCM.44.4.1602-1603.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Broad Differences between the COBAS Ampliprep Total Nucleic Acid Isolation-COBAS TaqMan 48 Hepatitis C Virus (HCV) and COBAS HCV Monitor v2.0 Assays for Quantification of Serum HCV RNA of Non-1 Genotypes

Top Letter References

 
Hepatitis C virus (HCV) RNA quantification is extensively used for therapeutic management of HCV chronic infection (1). The COBAS HCV Monitor v2.0 assay (HCM) was until recently one of the most used quantification methods worldwide. Two of its drawbacks are the labor-intensive manual extraction of HCV RNA and the frequent requirement of serum dilution for accurate quantification (>5.7 log₁₀ IU/ml) (4). The COBAS Ampliprep TNAI/COBAS TaqMan 48 Roche assay (CAPP-CTM) combines automated HCV RNA extraction with real-time PCR on the COBAS TaqMan 48 instrument (CTM48). It is one of the first platforms for clinical laboratories tending towards fully automated nucleic acid isolation and quantification, and it ensures a broad dynamic quantification range (43 to 69,000,000 IU/ml).

Therefore, we aimed to evaluate this new assay by measuring HCV RNA levels (VL) in sera from 93 patients previously tested using HCM (results range, 723 to 21,400,000 IU/ml). The HCV genotype was previously determined for each sample (7). Thirty-seven patients were infected with HCV genotype 1, and 56 were infected with an HCV non-1 genotype, including genotypes 2, 3, and 4 in 6, 33, and 17 cases, respectively.

No HCV sample was found below the quantification threshold of 43 IU per ml with CAPP-CTM. For patients infected with HCV genotype 1, Spearman's rank correlation coefficient was 0.941 (P < 0.01; R-square = 0.895), and the mean difference between RNA concentrations with CAPP-CTM and those with HCM was –0.11 ± 0.30 (range, –0.51 to 0.86); differences were between ±0.5 log₁₀ IU/ml for 89% of samples (Fig. 1, left). For patients infected with HCV non-1 genotypes, Spearman's rank correlation coefficient was 0.907 (P < 0.01; R-square = 0.836) and the mean difference was –0.77 ± 0.40 log₁₀ IU/ml (Fig. 1, right). Differences varied broadly according to individual samples (from –1.61 to 0.03); they exceeded –0.5 and –1.0 log₁₀ IU/ml in 71% and 30% of samples, respectively.

View larger version (14K): [in this window] [in a new window]

FIG. 1. Correlation between HCV RNA quantitative results using COBAS Amplicor HCV Monitor and COBAS Ampliprep TNAI/COBAS TaqMan 48 HCV assays for HCV genotype 1 (left) and non-1 genotype (right) strains. Dashed lines, virtual equivalence between the two assays; , genotype 2; , genotype 3; x, genotype 4.

Comparisons between VL measured with CTM48 and HCM were previously reported, but they focused only on clinical samples containing HCV genotype 1. They showed poor agreement, which differs from our findings. For instance, VL obtained with CTM48 were, on average, either twofold lower than with HCM or higher by +0.45 log₁₀, while large differences for individual samples were also observed (2, 3, 5). HCV RNA isolation procedures differed between the different studies, having been performed with either Roche MagNA Pure LC or QIAGEN BioRobot 9604 instruments. HCM was also found to overestimate a genotype 1 international standard concentration by approximately 0.5 log₁₀ (6).

Our findings revealed large underestimations of VL in clinical samples containing HCV genotypes 2, 3, and 4 with the CAPP-CTM assay in comparison with HCM, with large differences for individual samples. These genotypes represent approximately half of HCV-infected patients in our laboratory (7). Mean differences in VL between the two assays differ for samples infected with HCV 1 and non-1 genotypes. Thus, our data highlight the need for caution towards sequential measurements of non-1 genotype HCV RNA using different generations of Roche assays.

Top Letter References

 

1
1. Alberti, A., and L. Benvegnu. 2003. Management of hepatitis C. J. Hepatol. 38(Suppl. 1):S104-S118.
2
2. Barbeau, J. M., J. Goforth, A. M. Caliendo, and F. S. Nolte. 2004. Performance characteristics of a quantitative TaqMan hepatitis C virus RNA analyte-specific reagent. J. Clin. Microbiol. 42:3739-3746.[Abstract/Free Full Text]
3
3. Forman, M. S., and A. Valsamakis. 2004. Verification of an assay for quantification of hepatitis C virus RNA by use of an analyte-specific reagent and two different extraction methods. J. Clin. Microbiol. 42:3581-3588.[Abstract/Free Full Text]
4
4. Gourlain, K., A. Soulier, B. Pellegrin, M. Bouvier-Alias, C. Hezode, F. Darthuy, J. Remire, J. M. Pawlotsky, and the DITTP Group. 2005. Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay. J. Clin. Microbiol. 43:1669-1673.[Abstract/Free Full Text]
5
5. Konnick, E. Q., S. M. Williams, E. R. Ashwood, and D. R. Hillyard. 2005. Evaluation of the COBAS Hepatitis C Virus (HCV) TaqMan analyte-specific reagent assay and comparison to the COBAS Amplicor HCV Monitor V2.0 and Versant HCV bDNA 3.0 assays. J. Clin. Microbiol. 43:2133-2140.[Abstract/Free Full Text]
6
6. Pisani, G., K. Cristiano, M. Wirz, G. M. Bisso, and G. Gentili. 2002. Overestimation of the hepatitis C virus RNA content of reference preparations by the AMPLICOR HCV monitor test, version 2.0. J. Clin. Microbiol. 40:4765-4767.[Abstract/Free Full Text]
7
7. Tamalet, C., P. Colson, H. Tissot-Dupont, M. Henry, C. Tourres, N. Tivoli, D. Botta, I. Ravaux, I. Poizot-Martin, and N. Yahi. 2003. Genomic and phylogenetic analysis of hepatitis C virus isolates: a survey of 535 strains circulating in southern France. J. Med. Virol. 71:391-398.[CrossRef][Medline]

						Philippe Colson* Anne Motte Catherine Tamalet Laboratoire de Virologie Fédération Hospitalière de Bactériologie-Virologie  Clinique et d'Hygiène CHRU Timone 264 rue Saint-Pierre 13385 Marseille cedex 05 France
						* Phone: 33 491387969, Fax: 33 491385518, E-mail: Philippe.Colson{at}ap-hm.fr

---

Journal of Clinical Microbiology, April 2006, p. 1602-1603, Vol. 44, No. 4
0095-1137/06/$08.00+0     doi:10.1128/JCM.44.4.1602-1603.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Forman, M. S., Valsamakis, A. (2008). Performance Characteristics of a Quantitative Hepatitis C Virus RNA Assay Using COBAS AmpliPrep Total Nucleic Acid Isolation and COBAS TaqMan Hepatitis C Virus Analyte-Specific Reagent. J. Mol. Diagn. 10: 147-153 [Abstract] [Full Text]  

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Colson, P. Articles by Tamalet, C. Search for Related Content PubMed PubMed Citation Articles by Colson, P. Articles by Tamalet, C.